Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Datasets Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: NPH010
MIFTS: 50

Nephrosclerosis

Categories: Cardiovascular diseases, Nephrological diseases, Rare diseases
Genes Tissues Related diseases Publications Pathways Drugs
Sources

Aliases & Classifications for Nephrosclerosis

About this section

MalaCards integrated aliases for Nephrosclerosis:

Name: Nephrosclerosis 12 74 52 54 43 15 17 71
Renal Sclerosis 12

Classifications:

MalaCards categories:
Global: Rare diseases
Anatomical: Cardiovascular diseases Nephrological diseases
See all MalaCards categories (disease lists)
ICD10: 32


External Ids:

Disease Ontology 12 DOID:11664
ICD9CM 34 587
MeSH 43 D009400
SNOMED-CT 67 32916005
ICD10 32 I12
UMLS 71 C0027719
Sources

Summaries for Nephrosclerosis

About this section
MalaCards based summary : Nephrosclerosis, also known as renal sclerosis, is related to malignant hypertension and hypertensive nephropathy. An important gene associated with Nephrosclerosis is ACE (Angiotensin I Converting Enzyme), and among its related pathways/superpathways are TGF-Beta Pathway and p70S6K Signaling. The drugs Valsartan and Angiotensin II have been mentioned in the context of this disorder. Affiliated tissues include kidney, heart and pituitary, and related phenotypes are cardiovascular system and homeostasis/metabolism

Wikipedia : 74 Hypertensive kidney disease is a medical condition referring to damage to the kidney due to chronic high... more...

Sources

Related Diseases for Nephrosclerosis

About this section

Diseases related to Nephrosclerosis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 340)
# Related Disease Score Top Affiliating Genes
1 malignant hypertension 31.5 AGTR1 ADAMTS13 ACE
2 hypertensive nephropathy 31.2 VEGFA AGTR1 ACE
3 glomerular disease 31.1 NPHS2 NPHS1 ACE
4 nephrotic syndrome 31.1 SYNPO NPHS2 NPHS1 ACE
5 pyelonephritis 31.0 TNF TGFB1 CCL2 ACE
6 end stage renal disease 30.9 VEGFA TNF NPHS2 NPHS1 INS AGTR1
7 microvascular complications of diabetes 3 30.8 TGFB1 NPHS1 INS CCN2 AGTR1 ACE
8 rapidly progressive glomerulonephritis 30.8 TGFB1 NPHS1 MPO
9 focal segmental glomerulosclerosis 30.7 TGFB1 SYNPO NPHS2 NPHS1 AGTR1 ACE
10 iga glomerulonephritis 30.6 SYNPO NPHS2 NPHS1 AGTR1 ACE
11 glomerulonephritis 30.6 TGFB1 NPHS2 NPHS1 MPO CCN2 CCL2
12 arteriosclerosis 30.6 INS HIF1A F3 CCL2 ACE
13 hypertensive heart disease 30.5 NR3C2 AGTR1 ACE
14 thrombotic microangiopathy 30.5 VEGFA ADAMTS13
15 coronary heart disease 1 30.4 MTHFR INS AGTR1 ACE
16 vesicoureteral reflux 1 30.4 TGFB1 AGTR1 ACE
17 brucellosis 30.4 TNF TGFB1 MPO
18 hypertensive retinopathy 30.2 VEGFA AGTR1 ADAMTS13 ACE
19 proteasome-associated autoinflammatory syndrome 1 30.2 TNF MPO CCL2
20 renal hypertension 30.1 NPHS1 AGTR1 ADRB1 ACE2 ACE
21 membranous nephropathy 30.1 TNF NPHS2 NPHS1 MPO ACE
22 systemic scleroderma 30.1 TNF TGFB1 INS CCN2 ACE
23 deficiency anemia 30.1 TNF INS HIF1A ACE
24 ureteral obstruction 30.0 TGFB1 NR3C2 BMP7 AGTR1
25 disseminated intravascular coagulation 29.9 TNF F3 ADAMTS13
26 microvascular complications of diabetes 5 29.8 VEGFA INS HIF1A CCN2 AGTR1 ACE
27 autosomal dominant polycystic kidney disease 29.7 VEGFA TNF TGFB1 INS CCL2 AGTR1
28 pulmonary edema 29.7 TNF NR3C2 HIF1A AGTR1 ACE
29 anuria 29.6 NR3C2 F3 AGTR1 ADAMTS13 ACE
30 peripheral vascular disease 29.5 VEGFA MTHFR INS F3 CCL2 ACE
31 renal fibrosis 29.4 TNF TGFB1 NR3C2 HIF1A CCN2 CCL2
32 atherosclerosis susceptibility 29.3 VEGFA TNF MTHFR MPO INS F3
33 systemic lupus erythematosus 29.0 VEGFA TNF TGFB1 MPO INS F3
34 vascular disease 28.7 VEGFA TNF TGFB1 MTHFR MPO INS
35 kidney disease 28.7 TGFB1 NR3C2 NPHS2 NPHS1 MTHFR INS
36 chronic kidney disease 28.1 VEGFA TNF TGFB1 NR3C2 NPHS2 NPHS1
37 hypertension, essential 27.5 VEGFA TNF TGFB1 NR3C2 NPHS2 NPHS1
38 heart disease 27.1 VEGFA TNF TGFB1 NR3C2 MTHFR INS
39 lacrimoauriculodentodigital syndrome 11.3
40 familial vesicoureteral reflux 10.6 TGFB1 ACE
41 histoplasmosis pericarditis 10.6 TNF ACE
42 fibromuscular dysplasia 10.5 TGFB1 AGTR1 ACE
43 uveoparotid fever 10.5 TNF ACE
44 idiopathic nephrotic syndrome 10.5 TGFB1 NPHS2 ACE
45 subacute cutaneous lupus erythematosus 10.5 TNF ACE
46 diffuse scleroderma 10.5 TGFB1 CCN2 ACE
47 arteritic anterior ischemic optic neuropathy 10.5 MTHFR ACE
48 diffuse mesangial sclerosis 10.5 TGFB1 NPHS2 NPHS1
49 autoimmune inner ear disease 10.5 TNF MPO
50 familial nephrotic syndrome 10.5 SYNPO NPHS2 NPHS1

Comorbidity relations with Nephrosclerosis via Phenotypic Disease Network (PDN):


Acute Cystitis Acute Kidney Failure
Deficiency Anemia Heart Disease
Hydronephrosis Hypertension, Essential
Kidney Disease Nephrolithiasis, X-Linked Recessive, with Renal Failure

Graphical network of the top 20 diseases related to Nephrosclerosis:



Diseases related to Nephrosclerosis
Sources

Symptoms & Phenotypes for Nephrosclerosis

About this section

MGI Mouse Phenotypes related to Nephrosclerosis:

45 (show all 15)
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 10.42 ACE ACE2 ADRB1 AGTR1 BMP7 CCN2
2 homeostasis/metabolism MP:0005376 10.41 ACE ACE2 ADAMTS13 ADRB1 AGTR1 CCN2
3 growth/size/body region MP:0005378 10.39 ACE ACE2 ADRB1 AGTR1 BMP7 CCN2
4 mortality/aging MP:0010768 10.32 ACE ACE2 ADAMTS13 ADRB1 AGTR1 BMP7
5 hematopoietic system MP:0005397 10.27 ACE ADAMTS13 AGTR1 BMP7 F3 HIF1A
6 immune system MP:0005387 10.27 ACE ACE2 ADAMTS13 AGTR1 BMP7 CCL2
7 embryo MP:0005380 10.18 ACE BMP7 CCN2 F3 HIF1A INS
8 digestive/alimentary MP:0005381 10.14 ACE2 BMP7 CCN2 HIF1A INS TGFB1
9 integument MP:0010771 10.13 ACE2 BMP7 CCN2 F3 HIF1A INS
10 nervous system MP:0003631 10.03 AGTR1 BMP7 F3 HIF1A INS MTHFR
11 muscle MP:0005369 10.02 ACE2 ADRB1 F3 HIF1A INS MPO
12 liver/biliary system MP:0005370 10.01 ACE CCN2 HIF1A INS MTHFR TGFB1
13 renal/urinary system MP:0005367 9.93 ACE ACE2 AGTR1 BMP7 HIF1A INS
14 respiratory system MP:0005388 9.56 ACE2 BMP7 CCN2 F3 HIF1A TGFB1
15 vision/eye MP:0005391 9.32 ADAMTS13 BMP7 CCN2 F3 HIF1A INS
Sources

Drugs & Therapeutics for Nephrosclerosis

About this section

Drugs for Nephrosclerosis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 42)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Valsartan Approved, Investigational Phase 4 137862-53-4 60846
2
Angiotensin II Approved, Investigational Phase 4 4474-91-3, 11128-99-7, 68521-88-0 172198
3 Antihypertensive Agents Phase 4
4 Angiotensin II Type 1 Receptor Blockers Phase 4
5 Angiotensinogen Phase 4
6 Angiotensin Receptor Antagonists Phase 4
7 Giapreza Phase 4
8
Epoprostenol Approved Phase 2, Phase 3 35121-78-9, 61849-14-7 5282411 5280427
9
Metoprolol Approved, Investigational Phase 3 37350-58-6, 51384-51-1 4171
10
Amlodipine Approved Phase 3 88150-42-9 2162
11
Ramipril Approved Phase 3 87333-19-5 5362129
12 Tezosentan Investigational Phase 2, Phase 3 180384-57-0
13 Beraprost Investigational Phase 2, Phase 3 88430-50-6
14 Vasodilator Agents Phase 2, Phase 3
15 Platelet Aggregation Inhibitors Phase 2, Phase 3
16 Adrenergic beta-Antagonists Phase 3
17 Adrenergic beta-1 Receptor Antagonists Phase 3
18 1,4-dihydropyridine Phase 3
19 Angiotensin-Converting Enzyme Inhibitors Phase 3
20
protease inhibitors Phase 3
21 Adrenergic Antagonists Phase 3
22 Hormones Phase 3
23 Sympatholytics Phase 3
24 Adrenergic Agents Phase 3
25 Anti-Arrhythmia Agents Phase 3
26 HIV Protease Inhibitors Phase 3
27 Neurotransmitter Agents Phase 3
28 Calcium, Dietary Phase 3
29 calcium channel blockers Phase 3
30
Calcium Nutraceutical Phase 3 7440-70-2 271
31
Lovastatin Approved, Investigational 75330-75-5 53232
32
Atorvastatin Approved 134523-00-5 60823
33
Simvastatin Approved 79902-63-9 54454
34
Pravastatin Approved 81093-37-0 54687
35 Rosuvastatin Calcium 147098-20-2
36 Dihydromevinolin
37 Hypolipidemic Agents
38 Lipid Regulating Agents
39 Hydroxymethylglutaryl-CoA Reductase Inhibitors
40 Anticholesteremic Agents
41 Antimetabolites
42 L 647318

Interventional clinical trials:


# Name Status NCT ID Phase Drugs
1 Aldosterone Breakthrough During Diovan (Valsartan), Tekturna (Aliskiren), and Combination (Valsartan+Aliskiren) Anti-hypertensive Therapy in Patients With Proteinuric Kidney Disease Terminated NCT01129557 Phase 4 Aliskiren;Valsartan
2 TRK-100STP PhaseIIb/III Clinical Study - Chronic Renal Failure (Primary Glomerular Disease/Nephrosclerosis) Completed NCT01090037 Phase 2, Phase 3 TRK-100STP high dose;TRK-100STP low dose;Placebo
3 African American Study of Kidney Disease and Hypertension Completed NCT04364139 Phase 3 Ramipril;Amlodipine;Metoprolol
4 TRK-100STP PhaseII Clinical Study -Chronic Renal Failure (Primary Glomerular Disease/Nephrosclerosis) Completed NCT02480751 Phase 2 Beraprost;Placebo
5 Non-contrast Enhanced MR Imaging of the Kidney in Healthy Volunteers Completed NCT02618460
6 Use of High Potency Statins and Rates of Admission for Acute Kidney Injury: Multicenter, Retrospective Observational Analysis of Administrative Databases Completed NCT02518516 Rosuvastatin (≥10 mg);Atorvastatin (≥20 mg);Simvastatin (≥40 mg);Fluvastatin;Pravastatin;Lovastatin;Atorvastatin (<20mg);Simvastatin (<40 mg)
7 Prevalence of Normoalbuminuric Chronic Kidney Disease and Its Risk Factors in Patients With Type 2 Diabetes Attending the Diabetes Center of Assiut University Hospital Not yet recruiting NCT04411342

Search NIH Clinical Center for Nephrosclerosis

Cochrane evidence based reviews: nephrosclerosis

Sources

Genetic Tests for Nephrosclerosis

About this section
Sources

Anatomical Context for Nephrosclerosis

About this section

MalaCards organs/tissues related to Nephrosclerosis:

40
Kidney, Heart, Pituitary, Endothelial, Liver, Testes, Bone
Sources

Publications for Nephrosclerosis

About this section

Articles related to Nephrosclerosis:

(show top 50) (show all 1413)
# Title Authors PMID Year
1
[Profibrotic effects of aldosterone]. 54 61
15366722 2004
2
Collagen I upregulates extracellular matrix gene expression and secretion of TGF-beta 1 by cultured human mesangial cells. 61 54
14761892 2004
3
ACE inhibition is effective and renoprotective in hypertensive nephrosclerosis: the African American Study of Kidney Disease and Hypertension (AASK) trial. 61 54
12864879 2003
4
[Nephropathy associated with arterial hypertension: genes and Barker's hypothesis]. 61 54
12439839 2002
5
ACE inhibitors and appearance of renal events in hypertensive nephrosclerosis. 61 54
11566948 2001
6
Chronic proteinuric nephropathies: outcomes and response to treatment in a prospective cohort of 352 patients with different patterns of renal injury. 61 54
10845831 2000
7
Hypertension-induced organ damage in African Americans: transforming growth factor-beta(1) excess as a mechanism for increased prevalence. 61 54
10981147 2000
8
1,25-dihydroxyvitamin D3 stimulates transforming growth factor-beta1 synthesis by mouse renal proximal tubular cells. 61 54
10394107 1999
9
Effects of quinapril hydrochloride in patients with essential hypertension and impaired renal function. 61 54
9140710 1997
10
Short-term effects of blood pressure control and antihypertensive drug regimen on glomerular filtration rate: the African-American Study of Kidney Disease and Hypertension Pilot Study. 61 54
9159306 1997
11
Significance of increased accumulation of type VI collagen and transforming growth factor beta 1 in tubulointerstitial damage in hypertensive nephrosclerosis: an immunohistochemical study. 54 61
8737230 1996
12
Reversible renal insufficiency due to angiotensin converting enzyme inhibitors in hypertensive nephrosclerosis. 61 54
1883120 1991
13
Pharmacokinetics of dasatinib in a hemodialysis patient with chronic myeloid leukemia and chronic kidney disease. 61
32152879 2020
14
Endogenous miR-204 Protects the Kidney against Chronic Injury in Hypertension and Diabetes. 61
32487559 2020
15
Clinical value of multiorgan damage in hypertensive crises: A prospective follow-up study. 61
32271999 2020
16
Time-averaged proteinuria during follow-up and renal prognosis in patients with biopsy-proven benign nephrosclerosis. 61
32274596 2020
17
Premature vascular disease in young adult stroke: a pathology-based case series. 61
31853711 2020
18
Correlations Between Interleukin-11 Expression and Hypertensive Kidney Injury in a Rat Model of Renovascular Hypertension. 61
31840157 2020
19
Mortality patterns in patients with diabetes mellitus at a Nigerian tertiary hospital: A 10-Year autopsy study. 61
32295937 2020
20
Clinical Phenotypes and Long-term Prognosis in White Patients With Biopsy-Verified Hypertensive Nephrosclerosis. 61
32154455 2020
21
Pathogenesis of Fabry nephropathy: The pathways leading to fibrosis. 61
31718986 2020
22
Efficacy of mesenchymal stem cells in animal models of lupus nephritis: a meta-analysis. 61
32019582 2020
23
Kidney Structural Features from Living Donors Predict Graft Failure in the Recipient. 61
31974271 2020
24
Re: Larger Nephron Size, Low Nephron Number, and Nephrosclerosis on Biopsy as Predictors of Kidney Function after Donating a Kidney. 61
31671017 2020
25
Effects of Sustained-Release Beraprost in Patients With Primary Glomerular Disease or Nephrosclerosis: CASSIOPEIR Study Results. 61
31119846 2020
26
Detecting Proteomic Indicators to Distinguish Diabetic Nephropathy from Hypertensive Nephrosclerosis by Integrating Matrix-Assisted Laser Desorption/Ionization Mass Spectrometry Imaging with High-Mass Accuracy Mass Spectrometry. 61
32062660 2020
27
Application of explainable ensemble artificial intelligence model to categorization of hemodialysis-patient and treatment using nationwide-real-world data in Japan. 61
32469924 2020
28
Peritonitis due to Moraxella osloensis: A case report and literature review. 61
31196771 2019
29
Epidemiology and Pathophysiology of Glomerular C4d Staining in Native Kidney Biopsies. 61
31890997 2019
30
Glomerular solidification is associated with nephritis-related clinical parameters in IgA nephropathy. 61
31557071 2019
31
The effect of hemodialysis on ocular changes in patients with the end-stage renal disease. 61
31269848 2019
32
Progressive Nephron Loss in Aging Kidneys: Clinical-Structural Associations Investigated by Two Anatomical Methods. 61
31599090 2019
33
Successful Implementation of Unmanned Aircraft Use for Delivery of a Human Organ for Transplantation. 61
31663974 2019
34
The Key Role of Epithelial to Mesenchymal Transition (EMT) in Hypertensive Kidney Disease. 61
31330886 2019
35
Value of renal gene panel diagnostics in adults waiting for kidney transplantation due to undetermined end-stage renal disease. 61
31027891 2019
36
Clinicopathological predictors for progression of chronic kidney disease in nephrosclerosis: a biopsy-based cohort study. 61
29788462 2019
37
Larger nephron size, low nephron number, and nephrosclerosis on biopsy as predictors of kidney function after donating a kidney. 61
30629312 2019
38
Pathogenic role of angiotensin II and the NF-κB system in a model of malignant hypertensive nephrosclerosis. 61
30809002 2019
39
Higher rates of rejection in HIV-infected kidney transplant recipients on ritonavir-boosted protease inhibitors: 3-year follow-up study. 61
30864166 2019
40
Current status of vascular access in Japan-from Dialysis Access Symposium 2017. 61
31032732 2019
41
Amplified Association Between Blood Pressure and Albuminuria in Overweight Patients With Biopsy-Proven Hypertensive Nephrosclerosis. 61
30689693 2019
42
Post-Streptococcal Glomerulonephritis in Two Patients Following Deceased Donor Kidney Transplant. 61
31017877 2019
43
Knockout of receptor for advanced glycation end-products attenuates age-related renal lesions. 61
30794349 2019
44
The spectrum of kidney biopsy findings in patients with morbid obesity. 61
30712921 2019
45
Systemic Sarcoidosis Presenting with Renal Involvement Caused by Various Sarcoidosis-associated Pathophysiological Conditions. 61
30449791 2019
46
Key role of renal biopsy in management of progressive chronic kidney disease in liver graft recipients. 61
29946864 2019
47
Gene Expression Studies and Targeted Metabolomics Reveal Disturbed Serine, Methionine, and Tyrosine Metabolism in Early Hypertensive Nephrosclerosis. 61
30775629 2019
48
MiR-192-5p in the Kidney Protects Against the Development of Hypertension. 61
30595117 2019
49
A Case of Rheumatoid Arthritis Presenting with Renal Thrombotic Microangiopathy Probably due to a Combination of Chronic Tacrolimus Arteriolopathy and Severe Hypertension. 61
30963011 2019
50
Long-term patient follow-up after post-kidney transplant symptomatic lymphocele therapy. 61
31462054 2019
Sources

Variations for Nephrosclerosis

About this section
Sources

Expression for Nephrosclerosis

About this section
Search GEO for disease gene expression data for Nephrosclerosis.
Sources

Pathways for Nephrosclerosis

About this section

Pathways related to Nephrosclerosis according to GeneCards Suite gene sharing:

(show all 24)
# Super pathways Score Top Affiliating Genes
1
TGF-Beta Pathway 63
Show member pathways
 13.45 VEGFA TNF TGFB1 INS CCN2 CCL2
2
p70S6K Signaling 63
Show member pathways
 12.81 TGFB1 INS HIF1A CCN2 CCL2 BMP7
3
Allograft rejection 1 36
Show member pathways
 12.76 VEGFA TNF TGFB1 INS AGTR1
4
Proteoglycans in cancer 36
12.2 VEGFA TNF TGFB1 HIF1A
5
Folate Metabolism 1
Show member pathways
 12.16 TNF MTHFR MPO INS CCL2
6
Dilated cardiomyopathy (DCM) 36
Show member pathways
 12.15 TNF TGFB1 ADRB1 ACE
7
Adipogenesis 1
11.95 TNF TGFB1 INS HIF1A
8
Rheumatoid arthritis 36
11.75 VEGFA TNF TGFB1 CCL2
9
Angiogenesis (CST) 4
11.71 TGFB1 HIF1A F3 CCL2
10
Interleukin-4 and 13 signaling 65
11.71 VEGFA TNF TGFB1 HIF1A CCL2
11
Renin secretion 36
11.61 AGTR1 ADRB1 ACE
12
Endochondral Ossification 1
11.58 VEGFA TGFB1 BMP7
13
Primary Focal Segmental Glomerulosclerosis FSGS 1
11.57 TGFB1 SYNPO NPHS2 NPHS1
14
Agents Acting on the Renin-Angiotensin System Pathway, Pharmacodynamics 60
Show member pathways
 11.46 TGFB1 NR3C2 AGTR1 ACE2 ACE
15
Hepatitis C and Hepatocellular Carcinoma 1
11.45 VEGFA TGFB1 HIF1A
16
Malaria 36
11.43 TNF TGFB1 CCL2
17
Differentiation Pathway 1
11.4 VEGFA TGFB1 INS
18
amb2 Integrin signaling 1
11.39 TNF MPO CCN2
19
A-beta Uptake and Degradation 64
11.18 CCL2 ACE2 ACE
20
Lung fibrosis 1
11.15 TNF TGFB1 CCN2 CCL2 BMP7
21
AGE-RAGE signaling pathway in diabetic complications 36
11.1 VEGFA TNF TGFB1 F3 CCL2 AGTR1
22
G-protein signaling_Rap2B regulation pathway 22
10.89 TNF TGFB1 CCN2 CCL2 BMP7 ADRB1
23
LDL Oxidation in Atherogenesis 63
10.75 TNF MPO CCL2
24
miR-148a/miR-31/FIH1/HIF1andalpha;-Notch signaling in glioblastoma 1
10.56 VEGFA HIF1A
Sources

GO Terms for Nephrosclerosis

About this section

Cellular components related to Nephrosclerosis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.73 VEGFA TNF TGFB1 MPO INS F3
2 cell surface GO:0009986 9.63 VEGFA TNF TGFB1 F3 ADAMTS13 ACE2
3 extracellular space GO:0005615 9.4 VEGFA TNF TGFB1 MPO INS F3
4 slit diaphragm GO:0036057 9.26 NPHS2 NPHS1

Biological processes related to Nephrosclerosis according to GeneCards Suite gene sharing:

(show all 41)
# Name GO ID Score Top Affiliating Genes
1 signal transduction GO:0007165 10.19 VEGFA TGFB1 NR3C2 INS HIF1A CCN2
2 positive regulation of cell migration GO:0030335 9.98 VEGFA TGFB1 INS F3
3 positive regulation of ERK1 and ERK2 cascade GO:0070374 9.96 TNF TGFB1 CCN2 CCL2
4 positive regulation of protein phosphorylation GO:0001934 9.95 VEGFA TNF TGFB1 CCN2
5 positive regulation of protein kinase B signaling GO:0051897 9.93 TNF TGFB1 INS F3
6 response to hypoxia GO:0001666 9.92 VEGFA TGFB1 MTHFR HIF1A
7 positive regulation of endothelial cell proliferation GO:0001938 9.84 VEGFA HIF1A F3
8 cellular response to organic cyclic compound GO:0071407 9.83 TNF TGFB1 CCL2
9 positive regulation of MAP kinase activity GO:0043406 9.83 VEGFA TNF TGFB1
10 kidney development GO:0001822 9.83 VEGFA BMP7 AGTR1 ACE
11 positive regulation of protein complex assembly GO:0031334 9.82 VEGFA TNF TGFB1
12 positive regulation of blood vessel endothelial cell migration GO:0043536 9.79 VEGFA TGFB1 HIF1A
13 positive regulation of cell differentiation GO:0045597 9.77 INS CCN2 BMP7
14 epithelial to mesenchymal transition GO:0001837 9.77 TGFB1 HIF1A BMP7
15 regulation of cell proliferation GO:0042127 9.77 TNF TGFB1 HIF1A AGTR1 ACE2
16 positive regulation of pri-miRNA transcription by RNA polymerase II GO:1902895 9.75 TNF TGFB1 HIF1A
17 protein kinase B signaling GO:0043491 9.74 TNF TGFB1 CCL2
18 lipopolysaccharide-mediated signaling pathway GO:0031663 9.73 TNF TGFB1 CCL2
19 negative regulation of gene expression GO:0010629 9.73 VEGFA TNF TGFB1 HIF1A CCN2 ACE
20 positive regulation of positive chemotaxis GO:0050927 9.68 VEGFA F3
21 positive regulation of vascular permeability GO:0043117 9.68 VEGFA TGFB1
22 angiotensin maturation GO:0002003 9.68 ACE2 ACE
23 positive regulation of cardiac muscle contraction GO:0060452 9.67 CCN2 ACE2
24 negative regulation of production of miRNAs involved in gene silencing by miRNA GO:1903799 9.67 TNF TGFB1
25 salivary gland morphogenesis GO:0007435 9.67 TGFB1 BMP7
26 positive regulation of nitric-oxide synthase activity GO:0051000 9.65 TNF INS HIF1A
27 positive regulation of mononuclear cell migration GO:0071677 9.64 TNF TGFB1
28 positive regulation of transcription from RNA polymerase II promoter in response to hypoxia GO:0061419 9.63 VEGFA HIF1A
29 regulation of vasoconstriction GO:0019229 9.63 AGTR1 ACE2 ACE
30 cytokine-mediated signaling pathway GO:0019221 9.63 VEGFA TNF TGFB1 HIF1A F3 CCL2
31 connective tissue development GO:0061448 9.61 TGFB1 CCN2
32 connective tissue replacement involved in inflammatory response wound healing GO:0002248 9.61 TGFB1 HIF1A
33 regulation of blood vessel diameter GO:0097746 9.61 AGTR1 ACE2 ACE
34 positive regulation of peptidyl-tyrosine autophosphorylation GO:1900086 9.58 VEGFA ACE
35 camera-type eye morphogenesis GO:0048593 9.58 VEGFA HIF1A BMP7
36 receptor biosynthetic process GO:0032800 9.55 TNF ACE2
37 neural fold elevation formation GO:0021502 9.54 HIF1A BMP7
38 mononuclear cell proliferation GO:0032943 9.51 TGFB1 ACE
39 positive regulation of cellular protein metabolic process GO:0032270 9.5 TGFB1 INS AGTR1
40 positive regulation of gene expression GO:0010628 9.23 VEGFA TNF TGFB1 INS HIF1A F3
41 regulation of systemic arterial blood pressure by renin-angiotensin GO:0003081 9.13 AGTR1 ACE2 ACE

Molecular functions related to Nephrosclerosis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein binding GO:0005515 10.36 VEGFA TNF TGFB1 SYNPO NR3C2 NPHS2
2 heparin binding GO:0008201 9.62 VEGFA MPO CCN2 BMP7
3 growth factor activity GO:0008083 9.56 VEGFA TGFB1 CCN2 BMP7
4 exopeptidase activity GO:0008238 9.37 ACE2 ACE
5 peptidyl-dipeptidase activity GO:0008241 9.16 ACE2 ACE
6 cytokine activity GO:0005125 9.02 VEGFA TNF TGFB1 CCL2 BMP7
7 bradykinin receptor binding GO:0031711 8.96 AGTR1 ACE
Sources

Sources for Nephrosclerosis

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....